June 6, 2008 – The makers of the WaveSense™ line of blood glucose monitoring products (AgaMatrix, Inc.) announce the launch of the WaveSense Presto and WaveSense KeyNote Pro Blood Glucose Monitoring Systems (BGMS). The Presto is a no code meter with premium features that consumers can buy at a value price. The Pro is designed for use in institutional settings with added features for increased safety.
The Presto has all the market-leading features of AgaMatrix’s first product, the WaveSense KeyNote®, but does not require coding and is priced considerably less than no code products from the major brands. The system also has improved ergonomics and a brighter backlit display. Like the KeyNote, it requires a small sample size (0.5µl), is As Fast As 1-2-3®, and has alternate site testing. Presto builds on the existing base of WaveSense customers that is expected to exceed 1,000,000 by this fall... AgaMatrix's Press Release -
Blog Archive
-
▼
2008
(233)
-
▼
July
(23)
- MicroIslet : Safety and Efficacy Data Update
- CombinatoRx : Progress in Key Programs at 2008 R&D...
- Metabolon : Collaboration with the University of T...
- Santarus and Depomed : U.S. Promotion Agreement fo...
- International Stem Cell and Novocell : Collaborati...
- XOMA 052 Phase 1 Data to be Presented At European ...
- Hollis Eden Pharmaceuticals : Phase II Clinical Tr...
- Genaera : Data on Mechanism of Inhibition of PTP-1...
- Emisphere Technologies : Data From Independent Cli...
- Animas Corporation : OneTouch Ping Glucose Manage...
- Echo Therapeutics : Clinical Study of Its Symphony...
- BodyTel : to Launch GlucoTel System in August
- Axis-Shield : AFINION HbA1c patent granted in USA
- AgaMatrix : New WaveSense Presto and Pro Glucose M...
- ARKRAY USA : National Launch of GLUCOCARD X-METER
- Georgetown University Teams with Gentag and SAIC :...
- Emisphere : License Agreement With Novo Nordisk to...
- Debiotech and STMicroelectronics : First Prototype...
- Abbott : Phase III Sub-Group Analysis Shows Invest...
- ProStrakan : Novel Testosterone Gel Significantly ...
- Isis : Robust Drug Portfolio for Diabetes and Obes...
- Sangamo BioSciences : Presentation of Phase 1b ZFP...
- HemoCue : First FDA CLIA Waiver in Diagnostics Ind...
-
▼
July
(23)